A clinical trials agenda for testing interventions in earlier stages of psychotic disorders

Medical Journal of Australia

Volumn 190, Issue 4 SUPPL., 2009, Pages

  McGorry, Patrick D ^a,b   Yung, Alison R ^b   Pantelis, Christos ^a   Hickie, Ian B ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DOCOSAPENTAENOIC ACID; ESSENTIAL FATTY ACID; GLUCOCORTICOID ANTAGONIST; ICOSAPENTAENOIC ACID; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; TIANEPTINE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL RESEARCH; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIPID METABOLISM; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; OXIDATIVE STRESS; PSYCHOSIS; RESEARCH PRIORITY; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; STRESS MANAGEMENT;

EID: 61849144203     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02372.x     Document Type: Article

References (30)

1. Häfner H, Maurer K, Trendler G, et al. Schizophrenia and depression: challenging the paradigm of two separate diseases - a controlled study of schizophrenia, depression and healthy controls. Schizophr Res 2005; 77: 11-24.
2. McGorry PD, Purcell R, Hickie IB, et al. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust 2007; 187 (7 Suppl): S40-S42.
3. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004; 67: 131-142.
4. Yung AR, McGorry PD, McFarlane CA, et al. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996; 22: 283-303.
5. Edwards J, McGorry PD. Implementing early intervention in psychosis. A guide to establishing early psychosis services. London: Martin Dunitz, 2002.
6. Andrews G, Sanderson K, Corry J, et al. Cost-effectiveness of current and optimal treatment for schizophrenia. Br J Psychiatry 2003; 183: 427-435.
7. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003; 12: 22-33.
8. Insel TR. Beyond efficacy: the STAR D trial. Am J Psychiatry 2006; 163: 5-7.
9. Berger GE, Wood S, McGorry PD. Incipient neurovulnerability and neuroprotection in early psychosis. Psychopharmacol Bull 2003; 37: 79-101.
10. Yao JK, Reddy RD. Membrane pathology in schizophrenia: implication for arachidonic acid signaling. Scientific World Journal 2002; 2: 1922-1936.
11. Phillips LJ, McGorry PD, Garner B, et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006; 40: 725-741.
12. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull 2003; 29: 671-692.
13. Ng F, Berk M, Dean O, Bush A. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851-876.
14. Berger GE, Proffitt TM, McConchie M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1867-1875.
15. Amminger GP, Schäfer MR, Papageorgiou K, et al. Relationship between reduced erythrocyte membrane fatty acids and transition to psychosis in ultra high risk individuals [abstract]. Schizophr Res 2008; 98 Suppl 1: 108.
16. Berger GE, Wood SJ, Pantelis C, et al. Implications of lipid biology for the pathogenesis of schizophrenia. Aust N Z J Psychiatry 2002; 36: 355-366.
17. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatmerts for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007; 6: 21.
18. Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 2005; 45: 1-28.
19. Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005; 32: 173-202.
20. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
21. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241-1242.
22. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008; 105: 2052-2057.
23. Berger G, Dell'Olio M, Amminger P, et al. Neuroprotection in emerging psychotic disorders. Early Interv Psychiatry 2007; 1: 114-127.
24. Velakoulis D, Wood SJ, Wong MTH, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006; 63: 139-149.
25. Phillips LJ, McGarry PD, Garner B, et al. Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006; 40: 725-741.
26. Thompson KN, Phillips LJ, Komesaroff P, et al. Stress and HPA-axis functioning in young people at ultra high risk for psychosis. J Psychiatr Res 2007; 41: 561-569.
27. Thompson KN, Berger G, Phillips LJ, et al. HPA axis functioning associated with transition to psychosis: combined DEX/CRH test. J Psychiatr Res 2007; 41: 446-450.
28. Dupin N, Mailliet F, Rocher C, et al. Common efficacy of psychotropic drugs in restoring stress-induced impairment of prefrontal plasticity. Neurotox Res 2006; 10: 193-198.
29. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008; 64: 361-368.
30. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-475.